Effects of nanocurcumin supplementation on T‐helper 17 cells inflammatory response in patients with Behcet’s disease: a randomized controlled trial

References

• Alpsoy E. Behçet's disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol. 2016;43(6):620–632.
   PubMed Web of Science ®Google Scholar
• Yazici H. The lumps and bumps of Behcet’s syndrome. Autoimmun Rev. 2004;3(supplement 1):S53–S54.
   PubMedGoogle Scholar
• Wang HH, Dai YQ, Qiu W, et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci. 2011;18(10):1313–1317.
   PubMed Web of Science ®Google Scholar
• Lai NS, Yu HC, Chen HC, et al. Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributes to the immunopathogenesis. Clin Exp Immunol. 2013;173(1):47–57.
   PubMed Web of Science ®Google Scholar
• Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 2009;58(8):1152–1167.
   PubMed Web of Science ®Google Scholar
• Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763–776.
   PubMed Web of Science ®Google Scholar
• Hamburg JP, Tas SW. Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis. J Autoimmun. 2018;87:69–81.
   PubMed Web of Science ®Google Scholar
• Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008;8(5):337–348.
   PubMed Web of Science ®Google Scholar
• Hamzaoui K. Th17 cells in Behcet’s disease: a new immunoregulatory axis. Clin Exp Rheum. 2011;29(4 supplement 67):S71–S76.
   PubMed Web of Science ®Google Scholar
• Hamzaoui K, Bouali E, Ghorbel I, et al. Expression of Th-17 and RORγt mRNA in Behçet's Disease. Med Sci Monit. 2011;17(4):CR227–CR234.
   PubMed Web of Science ®Google Scholar
• Sugita S, Kawazoe Y, Imai A, et al. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease . Arthritis Res Ther. 2012;14(3):R99.
   PubMed Web of Science ®Google Scholar
• Geri G, Terrier B, Rosenzwajg M, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol. 2011;128(3):655–664.
   PubMed Web of Science ®Google Scholar
• Chi W, Yang P, Zhu X, et al. Production of interleukin-17 in behcet’s disease is inhibited by cyclosporin A. Mol Vis. 2010;16:880–886.
   PubMed Web of Science ®Google Scholar
• Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci. 2008;49(7):3058–3064.
   PubMed Web of Science ®Google Scholar
• Kuwabara T, Ishikawa F, Kondo M, et al. The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediators Inflamm. 2017;2017:3908061.
   PubMed Web of Science ®Google Scholar
• Qu N, Xu M, Mizoguchi I, et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Dev Immunol. 2013;2013:968549.
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201(2):233–240.
   PubMed Web of Science ®Google Scholar
• Hosseini A, Dolati S, Hashemi V, et al. Regulatory T and T helper 17 cells: their roles in preeclampsia. J Cell Physiol. 2018;233(9):6561–6573.
   PubMed Web of Science ®Google Scholar
• Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126(6):1121–1133.
   PubMed Web of Science ®Google Scholar
• Mehta A, Baltimore D. MicroRNAs as regulatory elements in immune system logic. Nat Rev Immunol. 2016;16(5):279–294.
   PubMed Web of Science ®Google Scholar
• Qu Z, Li W, Fu B. MicroRNAs in autoimmune diseases. Biomed Res Int. 2014;2014:527895.
   PubMed Web of Science ®Google Scholar
• Atabaki M, Shariati-Sarabi Z, Barati M, et al. MicroRNAs as the important regulators of T helper 17 cells: a narrative review. Iran J Allergy Asthma Immunol. 2020;19(6):589–601.
   PubMed Web of Science ®Google Scholar
• Na S, Park MJ, Park S, et al. MicroRNA-155 regulates the Th17 immune response by targeting ets-1 in behcet’s disease. Clin Exp Rheumatol. 2016;34(6 Suppl 102):S56–S63.
   PubMed Web of Science ®Google Scholar
• Kolahi S, Farajzadeh MJ, Alipour S, et al. Determination of mir-155 and mir-146a expression rates and its association with expression level of TNF-α and CTLA4 genes in patients with Behcet's disease . Immunol Lett. 2018;204:55–59.
   PubMed Web of Science ®Google Scholar
• El Boghdady NA, Shaker OG. Role of serum miR-181b, proinflammatory cytokine, and adhesion molecules in Behçet's disease. J Interferon Cytokine Res. 2019;39(6):347–354.
   PubMed Web of Science ®Google Scholar
• Jadideslam G, Ansarin K, Sakhinia E, et al. Expression levels of miR-21, miR-146b and miR-326 as potential biomarkers in Behcet's disease. Biomark Med. 2019;13(16):1339–1348.
   PubMed Web of Science ®Google Scholar
• Taylor J, Glenny AM, Walsh T, et al. Interventions for the management of oral ulcers in Behcet's disease. Cochrane Database Syst Rev. 2014;9:CD011018.
   Google Scholar
• Gul A. Pathogenesis of Behcet's disease: autoinflammatory features and beyond. Semin Immunopathol. 2015;37(4):413–418.
   PubMed Web of Science ®Google Scholar
• Kaklamani VG, Kaklamanis PG. Treatment of Behçet's disease-an update. Semin Arthritis Rheum. 2001;30(5):299–312.
   PubMed Web of Science ®Google Scholar
• Gautam SC, Gao X, Dulchavsky S. Immunomodulation by curcumin. Adv Exp Med Biol. 2007;595:321–341.
   PubMed Web of Science ®Google Scholar
• Yang M, Akbar U, Mohan C. Curcumin in autoimmune and rheumatic diseases. Nutrients. 2019;11(5):1004.
   Web of Science ®Google Scholar
• Bright JJ. Curcumin and autoimmune disease. Adv Exp Med Biol. 2007;595:425–451.
   PubMed Web of Science ®Google Scholar
• Handono K, Pratama MZ, Endharti AT, et al. Treatment of low doses curcumin could modulate Th17/Treg balance specifically on CD4+ T cell cultures of systemic lupus erythematosus patients . Cent Eur J Immunol. 2015;40(4):461–469.
   PubMed Web of Science ®Google Scholar
• Hajialilo M, Dolati S, Abdolmohammadi‐Vahid S, et al. Nanocurcumin: a novel strategy in treating ankylosing spondylitis by modulating Th17 cells frequency and function. J Cell Biochem. 2019;120(7):12027–12012.
   Web of Science ®Google Scholar
• Ahmadi M, Hajialilo M, Dolati S, et al. The effects of nanocurcumin on treg cell responses and treatment of ankylosing spondylitis patients: a randomized, double-blind, placebo-controlled clinical trial. J Cell Biochem. 2020;121(1):103–110.
   PubMed Web of Science ®Google Scholar
• Palizgir MT, Akhtari M, Mahmoudi M, et al. Curcumin reduces the expression of interleukin 1β and the production of interleukin 6 and tumor necrosis factor alpha by M1 macrophages from patients with behcet's disease. Immunopharmacol Immunotoxicol. 2018;40(4):297–302.
   PubMed Web of Science ®Google Scholar
• Abbasian S, Soltani-Zangbar MS, Khabbazi A, et al. Nanocurcumin supplementation ameliorates Behcet’s disease by modulating regulatory T cells: a randomized, double-blind, placebocontrolled trial. Int Immunopharmacol. 2021;101:108237.
   PubMed Web of Science ®Google Scholar
• International team for the revision of the international criteria for Behcet’s disease. Revision of the international criteria for Behcet’s disease (ICBD). Clin Exp Rheumatol. 2006;24(Suppl42):S14–S15.
   PubMedGoogle Scholar
• Davatchi F, Schirmer M, Zouboulis C, on behalf International Team for the Revision of the International Criteria for Behcet’s Disease, et al. “Evaluation and Revision of the International Study Group Criteria for Behçet’s Disease”. In: Proceedings of the American College of Rheumatology Meeting, 2007. Boston, Mass, USA. Abstract 1233.
   Google Scholar
• Davatchi F, Akbarian M, Shahram F, et al. Iran Behcet’s disease dynamic activity measure. Abstracts of the XIIth European congress of rheumatology. Hungarian Rheumatol. 1991;32:134. abstract FP10–100).
   Google Scholar
• Shahram F, Khabbazi A, Nadji A, et al. Comparison of existing disease activity indices in the follow-up of patients with Behcet’s disease. Mod Rheumatol. 2009;19(5):536–541.
   PubMed Web of Science ®Google Scholar
• Ahmadi M, Yousefi M, Abbaspour-Aghdam S, et al. Disturbed Th17/treg balance, cytokines, and miRNAs in peripheral blood of patients with Behcet's disease. J Cell Physiol. 2019;234(4):3985–3994.
   PubMed Web of Science ®Google Scholar
• Aktas Cetin E, Cosan F, Cefle A, et al. IL-22-secreting Th22 and IFN-γ-secreting Th17 cells in Behçet's disease. Mod Rheumatol. 2014;24(5):802–807.
   PubMed Web of Science ®Google Scholar
• Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007;13(2):139–145.
   PubMed Web of Science ®Google Scholar
• Golombick T, Diamond TH, Manoharan A, et al. B-cell disorders and curcumin. Integr Cancer Ther. 2017;16(3):255–257.
   PubMed Web of Science ®Google Scholar
• Wang J, Kang YX, Pan W, et al. Enhancement of anti-inflammatory activity of curcumin using phosphatidylserine-containing nanoparticles in cultured macrophages. IJMS. 2016;17(6):969.
   Google Scholar
• Fiala M. Curcumin and omega-3 fatty acids enhance NK cell-induced apoptosis of pancreatic cancer cells but curcumin inhibits interferon-γ production: benefits of omega-3 with curcumin against cancer. Molecules. 2015;20(2):3020–3026.
   PubMed Web of Science ®Google Scholar
• Lv J, Shao Q, Wang H, et al. Effects and mechanisms of curcumin and basil polysaccharide on the invasion of SKOV3 cells and dendritic cells. Mol Med Rep. 2013;8(5):1580–1586.
   PubMed Web of Science ®Google Scholar
• Ma C, Ma Z, Fu Q, et al. Curcumin attenuates allergic airway inflammation by regulation of CD4 + CD25+ regulatory T cells (tregs)/Th17 balance in ovalbumin-sensitized mice. Fitoterapia. 2013;87:57–64.
   PubMed Web of Science ®Google Scholar
• Zhao G, Liu Y, Yi X, et al. Curcumin inhibiting Th17 cell differentiation by regulating the metabotropic glutamate receptor-4 expression on dendritic cells. Int Immunopharmacol. 2017;46:80–86.
   PubMed Web of Science ®Google Scholar
• Park MJ, Moon SJ, Lee SH, et al. Curcumin attenuates acute graft-versus-host disease severity via in vivo regulations on Th1, Th17 and regulatory T cells. PLoS One. 2013;8(6):e67171.
   PubMed Web of Science ®Google Scholar
• Kalim H, Handono K, Khalasha T, et al. Immune modulation effects of curcumin in pristane-induced lupus mice. Indian J Rheumatol. 2017;12(2):86–93.
   Google Scholar
• Xie L, Li XK, Funeshima-Fuji N, et al. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int Immunopharmacol. 2009;9(5):575–581.
   PubMed Web of Science ®Google Scholar
• Bakır B, Yetkin Ay Z, Büyükbayram Hİ, et al. Effect of curcumin on systemic T helper 17 cell response; gingival expressions of interleukin-17 and retinoic acid Receptor-Related orphan receptor γt; and alveolar bone loss in experimental periodontitis. J Periodontol. 2016;87(11):e183–e191.
   PubMed Web of Science ®Google Scholar
• Dolati S, Aghebati-Maleki L, Ahmadi M, et al. Nanocurcumin restores aberrant miRNA expression profile in multiple sclerosis, randomized, double-blind, placebo-controlled trial. J Cell Physiol. 2018;233(7):5222–5230.
   PubMed Web of Science ®Google Scholar
• Dolati S, Ahmadi M, Rikhtegar R, et al. Changes in Th17 cells function after nanocurcumin use to treat multiple sclerosis. Int Immunopharmacol. 2018;61:74–81.
   PubMed Web of Science ®Google Scholar
• Hong J, Bose M, Ju J, et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis. 2004;25(9):1671–1679.
   PubMed Web of Science ®Google Scholar
• Jagetia GC, Aggarwal BB. "Spicing up" of the immune system by curcumin. J Clin Immunol. 2007;27(1):19–35.
   PubMed Web of Science ®Google Scholar
• Srivastava RM, Singh S, Dubey SK, et al. Immunomodulatory and therapeutic activity of curcumin. Int Immunopharmacol. 2011;11(3):331–341.
   PubMed Web of Science ®Google Scholar
• Antiga E, Bonciolini V, Volpi W, et al. Oral curcumin (meriva) is effective as an adjuvant treatment and is able to reduce IL-22 serum levels in patients with psoriasis vulgaris. Biomed Res Int. 2015;2015:1–7.
   Web of Science ®Google Scholar